| Company Name: |
Clearsynth Labs Limited
|
| Tel: |
+91-22-26355700 |
| Email: |
info@clearsynth.com |
| Products Intro: |
Product Name:MeloxicaM-D3
CAS:942047-63-4
Remarks:CS-O-01330
|
- Meloxicam D3
-
- $13000.00 / 10mg
-
2023-05-27
- CAS:942047-63-4
- Min. Order: 10mg
- Purity: 96%
- Supply Ability: 100
|
| | MELOXICAM-D3 Basic information |
| | MELOXICAM-D3 Chemical Properties |
| Melting point | 249-251°C | | storage temp. | -20°C Freezer | | solubility | DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml | | CAS DataBase Reference | 942047-63-4 |
| Hazard Codes | Xn | | Risk Statements | 22 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 |
| | MELOXICAM-D3 Usage And Synthesis |
| Description | Meloxicam-d3 is intended for use as an internal standard for the quantification of meloxicam by GC- or LC-MS. Meloxicam is a selective inhibitor of COX-2 (IC50s = 11.8 and 143 μM for COX-2 and COX-1, respectively, in an enzyme activity assay) and a non-steroidal anti-inflammatory drug (NSAID). Meloxicam (0.03%) reduces croton oil-induced increases in TNF-α and IL-1β mRNA levels and increases IL-10 mRNA levels in cornea in a rabbit model of acute ocular inflammation. It inhibits pleural plasma exudation in a carrageenan-induced rat model of pleurisy when administered at a dose of 3 mg/kg.In a canine model of unilateral osteoarthritis of the right stifle joint, meloxicam reduces prostaglandin E2 (PGE2) levels in plasma and right stifle joint synovial fluid when administered at a dose of 0.2 mg/kg. Formulations containing meloxicam have been used in the treatment of osteoarthritis and rheumatoid arthritis. | | Chemical Properties | Yellow Solid | | Uses | MELOXICAM-D3 is a preferential cyclooxygenase (COX-2) inhibitor,it is used as an anti-inflammatory. | | References | 1. Ogino, K., Hatanaka, K., Kawamura, M., et al. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 55, 44-53 (1997).
2. Cruz, R., Quintana-Hau, J.D., González, J.R., et al. Effects of an ophthalmic formulation of meloxicam on COX-2 expression, PGE2 release, and cytokine expression in a model of acute ocular inflammation. Br. J. Ophthalmol. 92, 120-125 (2008).
3. Jones, C.J., Streppa, H.K., Harmon, B.G., et al. In vivo effects of meloxicam and aspirin on blood, gasteric mucosal, and synovial fluid prosanoid synthesis in dogs. Am. J. Vet. Res. 63, 1527-1531 (2002). |
| | MELOXICAM-D3 Preparation Products And Raw materials |
|